Hemab Therapeutics Holdings, Inc. (COAG)
Nasdaq · Healthcare · Biotechnology
$30.59−1.67%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.4B
- 52-week range
- $23.00 – $55.42
- 52-week change
- −8.50%
- EPS (trailing)
- −$4.33
- Next earnings
- Nov 16, 2026
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 59 employees · hemab.com